(NASDAQ: SGMT) Sagimet Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.3%.
Sagimet Biosciences's earnings in 2026 is -$51,038,000.On average, 13 Wall Street analysts forecast SGMT's earnings for 2026 to be -$52,012,348, with the lowest SGMT earnings forecast at -$71,850,161, and the highest SGMT earnings forecast at -$37,977,942. On average, 13 Wall Street analysts forecast SGMT's earnings for 2027 to be -$61,344,722, with the lowest SGMT earnings forecast at -$101,228,893, and the highest SGMT earnings forecast at -$31,477,213.
In 2028, SGMT is forecast to generate -$68,392,881 in earnings, with the lowest earnings forecast at -$109,977,995 and the highest earnings forecast at -$29,424,352.